Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 132.94 $ -0.04 (-0.03 %)    

Tuesday, 25-Jun-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 132.92
$ 133.29
$ 132.91 x 100
$ 132.97 x 200
$ 132.62 - $ 134.61
$ 97.23 - $ 134.63
6,758,429
na
336.66B
$ 0.32
$ 145.99
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

merck--companys-merck-animal-health-received-approval-of-nobivac-nxt-canine-flu-h3n2-from-us-dept-of-agriculture
Merck & Company's Merck Animal Health Rece...
06/25/2024 20:06:30

Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease

analyst-sees-keros-therapeutics-as-next-acceleron-set-for-major-biotech-growth
Analyst Sees Keros Therapeutics As Next Ac...
06/25/2024 18:43:19

Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation....

gossamer-bios-clean-safety-profile-differentiates-it-from-merck-analyst-says
Gossamer Bio's Clean Safety Profile Differ...
06/25/2024 18:39:14

Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary art...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/25/2024 17:35:24

Core News & Articles
CORRECTION: Merck KGaA Ticker Is "MKGAF"
06/24/2024 17:06:47

5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more
5 Biotech Stocks With Key Catalysts This W...
06/24/2024 08:51:47

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 16:59:56

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

cracking-the-code-understanding-analyst-reviews-for-merck--co
Cracking The Code: Understanding Analyst R...
06/18/2024 21:00:57

competitor-analysis-evaluating-merck-amp-co-and-competitors-in-pharmaceuticals-industry
Competitor Analysis: Evaluating Merck &amp...
06/18/2024 15:00:37

covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment
Covid-19 Pharma Stars Continue Their Quest...
06/18/2024 14:19:12

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 12:08:42

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

fda-approves-mercks-pneumococcal-vaccine-as-first-shot-designed-for-adults
FDA Approves Merck's Pneumococcal Vaccine ...
06/18/2024 12:05:42

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains ...

Core News & Articles
FDA Approves CAPVAXIVE, Sixth Product Usin...
06/18/2024 12:03:40

merck-shares-are-trading-higher-after-the-fda-approved-capvaxive-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults
Merck shares are trading higher after the ...
06/18/2024 11:39:14

fda-approves-capvaxive-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults
FDA Approves CAPVAXIVE For Prevention Of I...
06/17/2024 21:31:48

CAPVAXIVE (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumoc...

fda-approves-mercks-keytruda-plus-carboplatin-paclitaxel-as-treatment-for-adult-patients-with-primary-advanced-or-recurrent-endometrial-carcinoma
FDA Approves Merck's KEYTRUDA Plus Carbopl...
06/17/2024 21:15:49

KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with prim...

merck--co-says-fda-approves-pembrolizumab-with-chemotherapy-for-primary-advanced-or-recurrent-endometrial-carcinoma-recommended-pembrolizumab-dose-is-200mg-every-3-weeks-or-400mg-every-6-weeks-until-disease-progression-unacceptable-toxicity-or-up-to-24-months
Merck & Co Says FDA Approves Pembrolizumab...
06/17/2024 16:32:03

- Reuters

merck--co-unusual-options-activity-for-june-14
Merck & Co Unusual Options Activity For Ju...
06/14/2024 18:15:51

how-is-the-market-feeling-about-merck--co
How Is The Market Feeling About Merck & Co?
06/11/2024 18:00:16

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION